Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
Lowering LDL-C: How low and for how long? | Professor Evan Stein
03:05
|
Download MP3
Related Videos
3:11
PCSK9 Forum Invitation | Professor John Chapman
6:46
PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment
1:21
PCSK9 Forum Invitation | Professor John Chapman
7:12
PCSK9 Forum News Editor Dr Peter Lansberg discusses ODYSSEY ESCAPE
3:34
How will PCSK9 inhibitors be used in practice?
1:43
Looking ahead with PCSK9 Education & Research Forum | Professor Henry Ginsberg
2:04
The PCSK9 Decade | Professor John Chapman
58:08
The Cholesterol Wars: Identifying Patients Who Would Most Benefit from PCSK9 Inhibitors (Part 1)
1:54
Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition
1:17
PCSK9 and Lp(a), a novel approach to a CV risk factor | Professor Henry Ginsberg
13:18
New era in cholesterol-lowering? PCSK9 inhibitors soon available?
2:05
Could PCSK9 inhibitors be used in children with FH
1:40
What are the gaps in knowledge about the PCSK9 inhibitors | Dr Evan Stein
7:20
Does PCSK9 have effects beyond the liver? | Professor Bertrand Cariou
2:36
Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?
44:18
2022 FORUM Sir Colin Dollery Lecture with Prof Dan Roden
3:55
Prof Kausik Ray gives an analysis of the PCSK9 inhibitor outcomes studies
1:38
Will PCSK9 monoclonal antibodies replace other lipid lowering treatment | Professor Frederick Raal
2:28
Weighing the cost versus benefit of PCSK9-targeted therapy | Professor Lluis Masana
3:34
How will FOURIER impact clinical practice, including treatment access?